Biochemical Pharmacology volume 81, issue 1, P50-59 2011 DOI: 10.1016/j.bcp.2010.09.006 View full text
|
|
Share
Philipp Saiko, Geraldine Graser, Benedikt Giessrigl, Andreas Lackner, Michael Grusch, Georg Krupitza, Arijit Basu, Barij Nayan Sinha, Venkatesan Jayaprakash, Walter Jaeger, Monika Fritzer-Szekeres, Thomas Szekeres

Abstract: Ribonucleotide reductase (RR; EC 1.17.4.1) is responsible for the de novo conversion of ribonucleoside diphosphates into deoxyribonucleoside diphosphates, which are essential for DNA replication. RR is upregulated in tumor cells and therefore considered to be an excellent target for cancer chemotherapy. ABNM-13 (N-hydroxy-2-(anthracene-2-yl-methylene)-hydrazinecarboximidamide), a novel N-hydroxy-N'-aminoguanidine has been designed to inhibit RR activity using 3D molecular space modeling techniques. In this stu…

expand abstract